Mikhail Yu. Valkov

Mikhail Yu. Valkov

Auto-generated profile, based on publicly available information

Mikhail Yu. Valkov

Northern State Medical University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Gynecologic Oncology
Verified
Journal Article
Open access
MMMelissa Matz
Melissa Matz
MCMichel P Coleman
Michel P Coleman
HCHelena Carreira
Helena Carreira
DSDiego Salmerón
Diego Salmerón
MCMaria Dolores Chirlaque
Maria Dolores Chirlaque
CLC. Lewis
C. Lewis
Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15-99years) diagnosed with ovarian cancer during 1995-2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Survival from type I epithelial ovarian tumours for women diagnosed during 2005-09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20-45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

1 February 2017 in Gynecologic Oncology
Verified
Journal Article
Open access
MMMelissa Matz
Melissa Matz
MCMichel P Coleman
Michel P Coleman
MSMilena Sant
Milena Sant
MCMaria Dolores Chirlaque
Maria Dolores Chirlaque
OVOtto Visser
Otto Visser
CLC. Lewis
C. Lewis
Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995-2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. During 2005-2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.

8 February 2018 in International Health
Verified
Journal Article
Closed access
PDF file
AGAndrej M Grjibovski
Andrej M Grjibovski
DDDaria Dubovichenko
Daria Dubovichenko
SSShynar Saduakassova
Shynar Saduakassova
GZGulmira Zhatkanbayeva
Gulmira Zhatkanbayeva
GOGulzhakhan Omarova
Gulzhakhan Omarova
MVMikhail Y Valkov
Mikhail Y Valkov
Cervical cancer is the third most common cancer among women. The evidence from Russia, however, is scarce. We studied the incidence of and mortality from cervical cancer in northwest Russia, and assessed determinants of survival among cervical cancer patients. This registry-based historical cohort study obtained data on all primary cases of cervical cancer in the Arkhangelsk region in 2000–2014 from the Arkhangelsk Regional Cancer Registry. One- and 5-y survival was calculated using life tables. Factors associated with survival were studied using Kaplan–Meier curves and Cox regression. The incidence increased from 10.9 per 100 000 in 2000 to 20.9 per 100 000 in 2014, while mortality increased from 2.0 to 7.8 per 100 000 during the same period. One- and 5-y survival was 77.4% (95% CI 75.4 to 79.4) and 60.0% (95% CI 54.6 to 61.5), respectively. Significant inverse association was observed between survival and stage of cancer. Patients with adenocarcinoma (HR=1.6, 95% CI 1.2 to 2.2), other histological types of cancer (HR=1.8, 95% CI 1.4 to 2.4) and those with undefined histologic type (HR=3.8, 95% CI 2.5 to 5.8) had shorter survival than patients with squamous cell carcinoma. Incidence of and mortality from cervical cancer in northwest Russia is considerably higher than in developed countries. Increased incidence in recent years may be attributed to increased screening.

2 September 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PJPhilipp Jaehn
Philipp Jaehn
SKSimone Kaucher
Simone Kaucher
LPLidia V. Pikalova
Lidia V. Pikalova
SMSofia Mazeina
Sofia Mazeina
HKHiltraud Kajüter
Hiltraud Kajüter
VWVolker Winkler
Volker Winkler
Few studies compared cancer incidence among migrants both to their host countries and to their population of origin. We aimed to compare cancer incidence of ethnic Germans who migrated from the former Soviet Union to Germany (resettlers) to those living in Russia as well as to the German and the Russian general populations. The cancer registry of North Rhine-Westphalia identified incident cases of stomach, colorectal, lung, breast and prostate cancer in resettlers and the general population of the administrative district of Münster (Germany) between 2004 and 2013. The Tomsk cancer registry collected the same data in ethnic Germans and the general population of the Tomsk region (Russia). We used standardised incidence rate ratios (SIRs) to compare rates of resettlers and ethnic Germans with the respective general populations. The total number of person-years under risk was 83,289 for ethnic Germans, 8,006,775 for the population of Tomsk, 219,604 for resettlers, and 20,516,782 for the population of Münster. Incidence of the five investigated cancer types among ethnic Germans did not differ from incidence of the general population of Tomsk. Compared to the general population of Tomsk, incidence among resettlers was higher for colorectal cancer in both sexes (females: SIR 1.45 [95% CI 1.14–1.83], males: SIR 1.56 [95% CI 1.23–1.97]), breast cancer in females (SIR 1.65 [95% CI 1.40–1.95]), and prostate cancer (SIR 1.64 [95% CI 1.34–2.01]). Incidence rates of these cancer types among resettlers were more similar to rates of the general population of Münster. Incidence of stomach and lung cancer did not differ between resettlers and the general population of Tomsk. After an average stay of 15 years, we observed that incidence of colorectal, breast and prostate cancer among resettlers converged to levels of the general population of Münster. Resettler’s incidence of stomach and lung cancer, however, was comparable to incidence in their population of origin. Causes must be investigated in subsequent analytical studies.

22 December 2020 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ЛВЛ. Е. Валькова
Л. Е. Валькова
MLM. L. Levit
M. L. Levit
VMV. M. Merabishvili
V. M. Merabishvili
APA. Yu. Pankrateva
A. Yu. Pankrateva
MKM. V. Krupina
M. V. Krupina
ВВВ. Ю. Вальков
В. Ю. Вальков
Динамика смертности от злокачественных новообразований, регистрируемых в ходе диспансеризации отдельных групп взрослого населения: популяционное исследование по данным архангельского областного канцер-регистра

1 January 2022 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
KKK. Kalyango
K. Kalyango
ADA.A. Dyachenko
A.A. Dyachenko
DBD.V. Bogdanov
D.V. Bogdanov
EPE.F. Potekhina
E.F. Potekhina
VMV.M. Merabishvili
V.M. Merabishvili
MVM.YU. Valkov
M.YU. Valkov
Распространенность и динамика отдельных морфологических вариантов нейроглиальных злокачественных новообразований головного мозга (ЗНО ГМ) (код С71 по МКБ-10) для популяции Российской Федерации неизвестна. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить динамику заболеваемости ЗНО ГМ в 2000—2020 гг. на основе индивидуальных записей морфологически верифицированных случаев в канцер-регистре Архангельской области. МАТЕРИАЛ И МЕТОДЫ Рассчитаны «грубые» и стандартизованные по возрасту (СПВ) (стандарт ВОЗ 2000 г.) показатели заболеваемости ЗНО ГМ в период с 2000 по 2020 г. в целом по группе С70—С71 и с учетом морфологических подтипов опухоли. Заболеваемость морфологически верифицированной глиобластомой (ГБ) детально оценена с учетом пола, возраста, места проживания. Для оценки динамики и значимости линейных трендов использовали сегментированный регрессионный анализ. РЕЗУЛЬТАТЫ Всего за период с 2000 по 2020 г. выявлено 1699 случаев ЗНО ГМ, морфологическая верификация получена у 1289 (76%) больных, из них у 467 (27%), 92 (5%) и 307 (18%) выявлены ГБ, анапластические глиомы G3 и глиомы G2 соответственно. Доля ГБ и анапластических глиом возросла с 23,4% и 3,9% в 2000 г. до 55,3% и 9,2% в 2020 г. соответственно. На фоне снижения СПВ показателей для всей группы С71 после 2015 г. с 5,2 до 3,2 случая на 100 тыс. населения (ежегодная убыль 7,1%) заболеваемость ГБ монотонно возрастала — с 1,0 до 2,1 случая на 100 тыс. населения (ежегодный прирост 6,2%). Не выявлены различия в заболеваемости между мужчинами и женщинами. Уровни СПВ показателей заболеваемости были на 50—70% выше среди сельского населения. ЗАКЛЮЧЕНИЕ Выявлен статистически значимый рост заболеваемости глиобластомой — более чем в 2 раза за последние 20 лет, связанный, вероятно, с улучшением диагностики и регистрации этого заболевания. Требуется углубленный анализ заболеваемости и выживаемости при редких опухолях нейроглии.